Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of 0.00% is 100% above its 5-year average of -1008.26%, near the high end of its 5-year range (-9471.19%–65.61%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
OPERATING MARGIN
0.00%
OPERATING MARGIN AVG TTM
0.00%
OPERATING MARGIN AVG 3Y
0.00%
OPERATING MARGIN AVG 5Y
-1008.26%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
+100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 745 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Fulcrum Therapeutics, Inc.
Market Cap
$282.68M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-1008.26%
Market Cap
$285.37M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$279.29M
Operating Margin
-14.55%
TTM Avg
-6.56%
3Y Avg
-30.72%
5Y Avg
-57.13%
Market Cap
$277.96M
Operating Margin
0.00%
TTM Avg
-1622.43%
3Y Avg
-1266.60%
5Y Avg
-841.86%
Market Cap
$287.54M
Operating Margin
-1536.91%
TTM Avg
-768.46%
3Y Avg
-1621.10%
5Y Avg
-1715.52%
Market Cap
$288.15M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
-384.25%
5Y Avg
-256.17%
Market Cap
$288.27M
Operating Margin
-109.34%
TTM Avg
-104.90%
3Y Avg
-100.12%
5Y Avg
-81.51%
Market Cap
$288.49M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$275.66M
Operating Margin
-2222.45%
TTM Avg
-1882.54%
3Y Avg
-1096.29%
5Y Avg
-863.53%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | $282.68M | 0.00% | 0.00% | 0.00% | -1008.26% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $285.37M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aurora Cannabis Inc. (ACB)vs › | $279.29M | -14.55% | -6.56% | -30.72% | -57.13% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $277.96M | 0.00% | -1622.43% | -1266.60% | -841.86% |
| Abeona Therapeutics Inc. (ABEO)vs › | $287.54M | -1536.91% | -768.46% | -1621.10% | -1715.52% |
| Sagimet Biosciences Inc. (SGMT)vs › | $288.15M | 0.00% | 0.00% | -384.25% | -256.17% |
| Standard BioTools Inc. (LAB)vs › | $288.27M | -109.34% | -104.90% | -100.12% | -81.51% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $288.49M | 0.00% | 0.00% | 0.00% | 0.00% |
| Fate Therapeutics, Inc. (FATE)vs › | $275.66M | -2222.45% | -1882.54% | -1096.29% | -863.53% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $274.22M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
0.0%
Operating Margin
0.0%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 65.61% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | -3213.78% |
| 2023-09-30 | -3615.28% |
| 2023-06-30 | -3101.36% |
| 2023-03-31 | -9471.19% |
| 2022-12-31 | -4083.65% |
| 2022-09-30 | -2058.75% |
| 2022-06-30 | -1819.08% |
| 2022-03-31 | -1003.01% |
| 2021-12-31 | -465.78% |
| 2021-09-30 | -420.87% |
| 2021-06-30 | -449.26% |
| 2021-03-31 | -355.88% |
| 2020-12-31 | -420.99% |
| 2020-09-30 | -1033.77% |
| 2020-06-30 | -796.20% |
| 2020-03-31 | -2506.13% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
